PL378435A1 - Nowe szczepy Bifidobacterium zdolne do wytwarzania glutaminy - Google Patents

Nowe szczepy Bifidobacterium zdolne do wytwarzania glutaminy

Info

Publication number
PL378435A1
PL378435A1 PL378435A PL37843504A PL378435A1 PL 378435 A1 PL378435 A1 PL 378435A1 PL 378435 A PL378435 A PL 378435A PL 37843504 A PL37843504 A PL 37843504A PL 378435 A1 PL378435 A1 PL 378435A1
Authority
PL
Poland
Prior art keywords
bifidobacterium
colitis
strains
days
patients
Prior art date
Application number
PL378435A
Other languages
English (en)
Other versions
PL212096B1 (pl
Inventor
Göran Molin
Siv Ahrne
Bengt Jeppsson
Original Assignee
Probi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probi Ab filed Critical Probi Ab
Publication of PL378435A1 publication Critical patent/PL378435A1/pl
Publication of PL212096B1 publication Critical patent/PL212096B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/529—Infantis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
PL378435A 2003-01-31 2004-01-27 Wyizolowane szczepy Bifidobacterium infantis i środek farmaceutyczny PL212096B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0300245A SE526711C2 (sv) 2003-01-31 2003-01-31 Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav
US44727403P 2003-02-14 2003-02-14

Publications (2)

Publication Number Publication Date
PL378435A1 true PL378435A1 (pl) 2006-04-03
PL212096B1 PL212096B1 (pl) 2012-08-31

Family

ID=20290264

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378435A PL212096B1 (pl) 2003-01-31 2004-01-27 Wyizolowane szczepy Bifidobacterium infantis i środek farmaceutyczny

Country Status (16)

Country Link
US (1) US7947482B2 (pl)
EP (1) EP1587913B1 (pl)
JP (1) JP4540664B2 (pl)
CN (1) CN100558883C (pl)
AT (1) ATE496115T1 (pl)
AU (1) AU2004208084B2 (pl)
BR (1) BRPI0407176B8 (pl)
CA (1) CA2514659C (pl)
DE (1) DE602004031079D1 (pl)
DK (1) DK1587913T3 (pl)
ES (1) ES2362496T3 (pl)
PL (1) PL212096B1 (pl)
RU (1) RU2352628C2 (pl)
SE (1) SE526711C2 (pl)
WO (1) WO2004067731A1 (pl)
ZA (1) ZA200505777B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1931363T3 (en) 2005-09-28 2016-02-22 Nordisk Rebalance As Treatment of IBD using both probiotic bacteria and fermented cereal as behandlingseffektorer
KR101300086B1 (ko) * 2005-10-06 2013-08-30 프로비 아베 자가면역질환의 치료를 위한 락토바실러스의 용도
CN105671120B (zh) * 2010-07-05 2019-02-19 株式会社明治 具有肠内腐败物质的减少作用的双歧杆菌
CL2010001124A1 (es) 2010-10-14 2011-01-21 Univ De Concepcion 50% Ma Loreto Ormeno 50% Alimento funcional probiotico que comprende cepas viables de lactobacillus sp.; uso de dicho alimento funcional para contrarestar los efectos colaterales de la quimioterapia.
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
CN103131647B (zh) * 2011-11-29 2017-06-27 上海上药信谊药厂有限公司 婴儿双歧杆菌及其制剂
IN2014DN07752A (pl) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
EP4529950A3 (en) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
CN108330166A (zh) * 2017-09-06 2018-07-27 深圳市百澳飞生物技术有限公司 一种酶制剂的饲用活性评估方法
CN113164526A (zh) 2018-07-19 2021-07-23 潘德勒姆治疗公司 用于微生物植入的方法和组合物
RU2699967C1 (ru) * 2018-12-25 2019-09-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ комплексного лечения энтеральной недостаточности у детей с тяжелой термической травмой
US11045507B2 (en) 2019-02-21 2021-06-29 Ewelina Sosnowska-Turek Bifidobacterium animalis AMT30 strain and the composition containing the strain of Bifidobacterium animalis AMT30
CN120924433A (zh) * 2025-07-23 2025-11-11 江南大学 一株降低由雌激素水平低造成的相关代谢紊乱发生风险的青春双歧杆菌及应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59155321A (ja) * 1983-02-25 1984-09-04 Riyoushiyoku Kenkyukai 整腸用製剤
DE3406772A1 (de) * 1984-02-24 1986-03-13 Angelo 8137 Berg Schuler Diaetetisches mittel zur herabsetzung der harnstoffkonzentration in koerperfluessigkeiten und seine herstellung
SE9002732D0 (sv) 1990-08-24 1990-08-24 Kabivitrum Ab Product containing growth factor
IT1254210B (it) 1992-02-10 1995-09-14 Simone Claudio De Composizioni dietetiche e/o farmaceutiche a base di batteri lattici liofilizzati, loro preparazione e impiego
JP3623977B2 (ja) * 1993-10-29 2005-02-23 明治乳業株式会社 潰瘍性大腸炎治療剤
JP4852681B2 (ja) * 1996-02-28 2012-01-11 雪印メグミルク株式会社 腸管内細胞溶解活性抑制剤
IT1288119B1 (it) 1996-06-28 1998-09-10 Renata Maria Anna Ve Cavaliere Composizioni dietetiche da utilizzare nell'alimentazione per via enterica
RU2112034C1 (ru) * 1996-12-26 1998-05-27 Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского Штамм bifidobacterium infantis 73-15, используемый для приготовления бифидосодержащих бактерийных препаратов и продуктов лечебно-диетического питания
CN1099289C (zh) * 1997-08-01 2003-01-22 北京东方百信生物技术有限公司 改善肠道生态平衡的微生物制剂及其工艺
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
ATE425244T1 (de) * 1999-08-05 2009-03-15 Nestle Sa Bifidobacteria zum vorbeugen von diarrhöe infolge pathogener bakterien
US6468525B1 (en) 1999-08-10 2002-10-22 Renew Life, Inc. Probiotic formulation
AU2001262966A1 (en) 2000-05-03 2001-11-12 University Of Maryland, Baltimore Oral gram (+) bacteria and glutamine composition for prevention and/or treatmentof gastro-intestinal dysfunctions including inflammation in the gastro-intestin al tract, neonatal necrotizing enterocolitis (nec) and bacterial sepsis
WO2002003879A1 (en) * 2000-07-07 2002-01-17 First Circle Medical, Inc. Treatment of hiv using hyperthermia
JP2002186422A (ja) * 2000-12-22 2002-07-02 Morinaga Milk Ind Co Ltd ラクトバシラス・ガッセリ及びビフィドバクテリウム属の菌を含有する非発酵食品
FI109602B (fi) 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
KR100845456B1 (ko) * 2001-02-06 2008-07-10 소시에떼 데 프로듀이 네슬레 소시에떼아노님 젖산균 및 비피도균에 의한 내독소 결합
US20030017192A1 (en) * 2001-06-19 2003-01-23 Hanny Kanafani Process for producing extended shelf-life ready-to-use milk compositions containing probiotics
US20030092163A1 (en) * 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
JP3364491B2 (ja) * 2002-07-25 2003-01-08 株式会社アトリエ・ド・フロマージュ ヨーグルトおよびその製造方法

Also Published As

Publication number Publication date
BRPI0407176A (pt) 2006-02-07
RU2005127331A (ru) 2006-01-27
JP4540664B2 (ja) 2010-09-08
CA2514659C (en) 2014-07-08
SE0300245D0 (sv) 2003-01-31
BRPI0407176B8 (pt) 2021-05-25
US7947482B2 (en) 2011-05-24
EP1587913A1 (en) 2005-10-26
US20060269533A1 (en) 2006-11-30
SE526711C2 (sv) 2005-10-25
RU2352628C2 (ru) 2009-04-20
EP1587913B1 (en) 2011-01-19
PL212096B1 (pl) 2012-08-31
CN1777670A (zh) 2006-05-24
BRPI0407176B1 (pt) 2018-05-08
WO2004067731A1 (en) 2004-08-12
JP2006516405A (ja) 2006-07-06
AU2004208084A1 (en) 2004-08-12
SE0300245L (sv) 2004-08-01
DE602004031079D1 (de) 2011-03-03
CN100558883C (zh) 2009-11-11
ATE496115T1 (de) 2011-02-15
ZA200505777B (en) 2007-12-27
ES2362496T3 (es) 2011-07-06
CA2514659A1 (en) 2004-08-12
DK1587913T3 (da) 2011-04-11
AU2004208084B2 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
FI90086C (fi) Foerfarande foer isolering av en terapeutiskt anvaendbar lactobacillus acidophilus -stam
SE0300245D0 (sv) New strains 1
RU2465320C2 (ru) Композиция штаммов рода lactobacillus для производства лекарственного средства
EP3863656A1 (en) Methods of treatment of inflammatory conditions and associated infections
Kim et al. Lactobacillus brevis OK56 ameliorates high-fat diet-induced obesity in mice by inhibiting NF-κB activation and gut microbial LPS production
CN113755409A (zh) 一种缓解胰岛素抵抗的长双歧杆菌及其应用
CN108402371A (zh) 一种适合中老年便秘人群服用的益生元组合物
CN108836956B (zh) 甘草查耳酮a在制备治疗鸡坏死性肠炎药物中的用途
CN108157703A (zh) 一种蔓越莓菊粉益生菌固体饮料及其制备方法
JP3623977B2 (ja) 潰瘍性大腸炎治療剤
CA3232874A1 (en) Hygromycin a for treatment of diseases and infections
CN118360221A (zh) 一株卷曲乳杆菌ncu-23及其应用
CN108309969B (zh) 鸢尾黄素在治疗鸡坏死性肠炎中的医用用途
KIRBY et al. Treatment of staphylococcic infections with erythromycin
JP7118594B2 (ja) 止瀉剤組成物
CN105343132B (zh) 治疗结肠炎的组合物、药物及其制备方法
Ismail Hyperbaric oxygen therapy as a complementary or alternative therapy for chronic oral and gastrointestinal disorders: A narrative review
Marshall Jr et al. The variable effects of sulfonamides on fecal bacteria in patients with chronic ulcerative colitis: a preliminary report
Snel et al. The influence of indigenous segmented filamentous bacteria on small intestinal transit in mice
JP2007522075A (ja) 肝不全の治癒並びに肝臓代謝の再生及び強化のためのエンテロコッカス・フェシウム（ＥｎｔｅｒｏｃｏｃｃｕｓＦａｅｃｉｕｍ）菌株の使用
JP4868378B2 (ja) 炎症性腸疾患治療薬
Zhou et al. Administration of probiotics reduces bacterial translocation after intestinal transplantation in rats
PAQUIN ANTI-TUBERCLE SERUM. THE TREATMENT OF CONSUMPTION BY SEROTHERAPY—REPORT AND PRESENTATION OF CASES TREATED—EXHIBITION OF SERUM, ETC.
CN120249099A (zh) 一株罗伊氏粘液乳杆菌ccfm1453制备的促进胃黏膜修复的多糖
CN120168459A (zh) 独活素在制备治疗和/或缓解新生儿感染性疾病及脏器损伤的药物中的应用

Legal Events

Date Code Title Description
RECP Rectifications of patent specification